Key result
Addition of amlodipine 2.5 mg or valsartan 40 mg to standard antihypertensive therapy improved diastolic dysfunction, but the change in E/E' ratio did not differ significantly between groups (p=0.25).
Why the study?
Hypertensive patients have an increased risk of diastolic dysfunction, and it was hypothesized that adding amlodipine would be superior to valsartan for improving hypertension-associated diastolic dysfunction.
Does amlodipine improve diastolic dysfunction compared to valsartan in controlled hypertensive patients?
RCT (n=104)
Open-label
1:1
Yes
Does amlodipine improve diastolic dysfunction compared to valsartan in controlled hypertensive patients?
Addition of low-dose amlodipine or valsartan to standard antihypertensive therapy significantly improves diastolic dysfunction in controlled hypertensive patients, with no significant difference between the two agents.
Either low-dose amlodipine or valsartan addition improves diastolic dysfunction similarly in controlled hypertension; extends add-on options without agent preference.
BACKGROUND: Hypertensive patients are at increased risk of diastolic dysfunction. The hypothesis of this study was that addition of amlodipine would be superior to valsartan in improving diastolic dysfunction associated with hypertension. METHODS: In this randomized trial, we randomly assigned 104 controlled, hypertensive patients with diastolic dysfunction to receive either amlodipine 2.5 mg or valsartan 40 mg, in addition to antihypertensive therapy. The primary end point was the change in the ratio of early mitral inflow velocity to early mitral annular relaxation velocity (E/E') from baseline to the 6-month follow-up. Secondary end points included changes in systolic blood pressure (SBP), left ventricular (LV) mass index, and left atrial volume index. RESULTS: SBP decreased significantly from baseline in both treatment groups (p < 0.001). E/E' decreased significantly from 13.0 ± 2.2 to 12.0 ± 2.7 in the amlodipine arm and from 14.4 ± 4.3 to 12.7 ± 3.7 in the valsartan arm (p < 0.01 in both groups). The change of E/E' was not significantly different between treatment groups (p = 0.25). There were also no significant between-group differences regarding the changes in SBP, LV mass index, and left atrial volume index. Two patients (3.8%) in the amlodipine group and 1 (16%) in the valsartan group had serious adverse event. CONCLUSIONS: In this randomized trial involving controlled hypertensive patients, addition of amlodipine or valsartan was associated with an improvement of diastolic dysfunction, but the effects on diastolic dysfunction did not differ significantly between the treatment groups.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2020) conducted an RCT in Hypertension with diastolic dysfunction (n=104). Amlodipine vs. Valsartan 40 mg daily was evaluated on Change in the ratio of early mitral inflow velocity to early mitral annular relaxation velocity (E/E′) from baseline to 6-month follow-up (p=0.25). Addition of amlodipine 2.5 mg or valsartan 40 mg to standard antihypertensive therapy improved diastolic dysfunction, but the change in E/E' ratio did not differ significantly between groups (p=0.25).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: